Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D9NY
|
|||
| Former ID |
DNCL001723
|
|||
| Drug Name |
Bempedoic acid
|
|||
| Synonyms |
ETC-1002; bempedoic acid; 738606-46-7; 8-Hydroxy-2,2,14,14-tetramethylpentadecanedioic acid; ESP-55016; UNII-1EJ6Z6Q368; ETC 1002; Bempedoic acid; ESP-55016; 1EJ6Z6Q368; Bempedoate; Bempedoic acid [USAN:INN]; ETC1002; ESP 55016; Bempedoic acid (USAN/INN); SCHEMBL185768; GTPL8321; CHEMBL3545313; HYHMLYSLQUKXKP-UHFFFAOYSA-N; EX-A1243; ZINC3948738; BCP16083; s7953; AKOS027439916; CS-3952; DB11936; AK499358; AC-29040; AS-49804; HY-12357; Bempedoic Acid(ETC-1002;ESP-55016); D10691; Pentadecanedioic acid, 8-hydroxy-2,2,14,14-tetramethyl-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Familial hypercholesterolemia [ICD-11: 5C80.00; ICD-10: E78.0; ICD-9: 272] | Approved | [1] | |
| Cardiovascular disease [ICD-11: BA00-BE2Z; ICD-10: I00-I99, E78; ICD-9: 390-459] | Phase 3 | [2] | ||
| Company |
Esperion Therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H36O5
|
|||
| Canonical SMILES |
CC(C)(CCCCCC(CCCCCC(C)(C)C(=O)O)O)C(=O)O
|
|||
| InChI |
1S/C19H36O5/c1-18(2,16(21)22)13-9-5-7-11-15(20)12-8-6-10-14-19(3,4)17(23)24/h15,20H,5-14H2,1-4H3,(H,21,22)(H,23,24)
|
|||
| InChIKey |
HYHMLYSLQUKXKP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 738606-46-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:149601
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | ATP-citrate synthase (ACLY) | Target Info | Inhibitor | [1] |
| Cholesterol synthesis (Chole synth) | Target Info | Inhibitor | [1] | |
| BioCyc | Acetyl-CoA biosynthesis from citrate | |||
| KEGG Pathway | Citrate cycle (TCA cycle) | |||
| Metabolic pathways | ||||
| Biosynthesis of antibiotics | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Pathwhiz Pathway | Transfer of Acetyl Groups into Mitochondria | |||
| Reactome | ChREBP activates metabolic gene expression | |||
| Fatty Acyl-CoA Biosynthesis | ||||
| WikiPathways | Fatty Acid Biosynthesis | |||
| TCA Cycle and PDHc | ||||
| Butyrate-induced histone acetylation | ||||
| SREBP signalling | ||||
| Integration of energy metabolism | ||||
| Fatty acid, triacylglycerol, and ketone body metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.